Literature DB >> 26978876

OCULAR AND OSTEOARTICULAR TUBERCULOSIS IN A YOUNG PATIENT. CASE REPORT.

Dragosloveanu Serban, Christiana Celea, Cristian Celea.   

Abstract

CASE REPORT: A young healthy patient, health-care worker in a state hospital, presented in the eye department complaining of pain and blurred vision in the left eye for approx. 2 weeks. Examination revealed a VA of 12/20 in the left eye, an interstitial keratitis, some signs of vitreal inflammation and two chorioretinal mass lesions (at echography appearing cystic) in the affected eye. She also mentioned a chronic pain in the right wrist. No systemic association was found. Based on the orthopaedic examination, biopsy, and surgical intervention, a strong suspicion of ocular tuberculosis was made and the patient was advised to start tuberculostatic treatment for 12 months and ocular steroidian treatment for 4 months. The ocular manifestations regressed totally after 3 months of treatment, the VA of the left eye improving at 20/ 20.
CONCLUSION: Tuberculosis can present many manifestations, with multi systemic involvement. Ocular tuberculosis is a difficult diagnosis and thus requires thorough multi-disciplinary investigations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26978876      PMCID: PMC5712931     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  4 in total

Review 1.  Intraocular tuberculosis--an update.

Authors:  Vishali Gupta; Amod Gupta; Narsing A Rao
Journal:  Surv Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 6.048

2.  Interferon-gamma release assays in the diagnosis of tuberculous uveitis.

Authors:  Thomas A Albini; Petros C Karakousis; Narsing A Rao
Journal:  Am J Ophthalmol       Date:  2008-10       Impact factor: 5.258

3.  Ocular manifestations of tuberculosis.

Authors:  S J Sheu; J S Shyu; L M Chen; Y Y Chen; S C Chirn; J S Wang
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

Review 4.  Ocular tuberculosis masquerading as ocular tumors.

Authors:  Hakan Demirci; Carol L Shields; Jerry A Shields; Ralph C Eagle
Journal:  Surv Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 6.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.